Custom service

Custom Hybridoma Optimization

Rescue a drifting clone, or rebuild one that stopped performing.

Timeline: 4–8 weeks — per optimisation cyclePassages: ≥20 — stability documentedServices: Subcloning, adaptation — isotype switch, rescue

A hybridoma is a living reagent, and living reagents drift. Antibody titre falls after prolonged culture, a subpopulation overgrows and stops secreting, mycoplasma contamination silently reduces yield, and a clone that worked in RPMI with 10% serum fails when the process moves to serum-free suspension. None of these are failures of the antibody; they are failures of the cell line, and most are fixable.

Optimisation starts with a diagnosis. We measure specific productivity per cell, check for mycoplasma and for chromosomal drift by isotype stability, and compare the current passage with an early frozen stock. If an early vial exists, the simplest fix is often to go back to it and re-establish a working bank under conditions that will be used going forward.

Where the clone itself is the problem, the work is more structural: two to three rounds of limiting dilution to isolate a high-secreting subclone, adaptation to serum-free suspension over four to six passages, and where necessary an isotype switch or a fusion of the existing hybridoma with a fresh myeloma partner to restore stability.

Service Highlights

Where it fits

Optimisation is worth doing whenever a hybridoma is the long-term supply route for a product or a diagnostic. It is also the right response to a sudden drop in titre, to a contamination event, or to a process transfer that requires serum-free suspension culture.

It is not worth doing when the antibody itself is mediocre. Subcloning improves yield and stability, not affinity or specificity; if the clone is weak, the money is better spent on a new campaign or on recombinant expression from the existing sequence.

Documentation and QC

Each optimisation cycle is reported with growth curves, specific productivity before and after, mycoplasma and sterility results, isotype confirmation, and a stability data set covering at least twenty passages. Bank records include passage number and viable cell count at freeze.

Frequently asked questions

Can a contaminated hybridoma be saved?

Mycoplasma can sometimes be cleared with antibiotic treatment, but the cure is unreliable and the line may remain compromised. If an early clean vial exists, restarting from it is almost always the better option.

How much can titre be improved?

Two- to five-fold is typical from subcloning alone, and more when serum-free adaptation removes the growth-inhibitory effect of high serum. We measure before and after rather than quoting a figure.

Do you provide the cell line or only the antibody?

Either. The optimised line and its banks can be transferred to you, with a material transfer agreement, so that production continues in your facility.

Send a vial and its passage history. If the line cannot be recovered, the sequence is still worth having — recombinant expression is often the more durable answer.

Service Highlights

  • Productivity per cell. Specific antibody secretion measured rather than inferred from titre, which separates a slow-growing high-producer from a fast-growing low-producer.
  • Subcloning to homogeneity. Two to three rounds of limiting dilution with screening at each round, so a stable high-secreting line is selected rather than assumed.
  • Serum-free adaptation. Stepwise weaning over four to six passages, with viability and titre monitored at each step.
  • Contamination screening. Mycoplasma by PCR and culture, plus sterility and cell line identity checks.
  • Isotype switching. Class switch to IgG1, IgG2a or IgA where the assay requires a different Fc.
  • Banking. A two-tier bank — master and working — with passage number, viability and productivity recorded for each vial.

How the work runs

  1. Diagnosis

    Growth curve, viability, specific productivity, mycoplasma status and isotype stability are measured against the original frozen stock.

  2. Recovery from early stock

    Where an early passage vial exists, the line is re-established from it and a fresh master bank prepared before any further manipulation.

  3. Subcloning

    Limiting dilution at 0.3–0.5 cells per well, with supernatant screening by ELISA; the highest specific producers are expanded.

  4. Adaptation

    Serum reduction in steps, then suspension adaptation in shaker flasks or a stirred bioreactor, with growth rate and titre tracked.

  5. Stability study

    Twenty or more passages with periodic titre and isotype checks to confirm that productivity does not decay.

  6. Banking and documentation

    Master and working banks frozen in medium with 10% DMSO, with full records for each vial.

Specifications & timeline

Timeline
4–8 weeks — per optimisation cycle
Passages
≥20 — stability documented
Services
Subcloning, adaptation — isotype switch, rescue
Services
Subcloning, serum-free adaptation, mycoplasma screening, isotype switch, cell line rescue
Subcloning
Limiting dilution at 0.3–0.5 cells/well, 2–3 rounds with ELISA screening
Adaptation
Serum-free suspension over 4–6 passages, shaker flask or stirred bioreactor
Stability
20–60 passages with titre, growth rate and isotype monitored
Timeline
4–8 weeks per optimisation cycle
Deliverables
Optimised line, master and working banks, productivity data, sterility report

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.